NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours

Oncology Reports

Volumn 25, Issue 1, 2011, Pages 281-288

  Indrová, Marie ^a   Símová, Jana ^a   Bieblová, Jana ^a   Bubeník, Jan ^a   Reinis, Milan ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

CD4+; CD8+; Interferon ; MHC class I deficient tumours; NK1.1 + cell subpopulations

Indexed keywords

GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL LINEAGE; CELL POPULATION; CYTOTOXICITY; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNITY; IMMUNIZATION; IRRADIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE SUBPOPULATION; TUMOR GROWTH;

ANIMALS; ANTIGENS, LY; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMAN PAPILLOMAVIRUS 16; KILLER CELLS, NATURAL; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY B;

EID: 78650726706     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00001072     Document Type: Article

References (29)

1. Levitsky HI, Lazenby A, Hayashi RJ and Pardoll DM: In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 179: 1215-1224, 1994.
2. Cheng WF, Hung CF, Lin KY, Ling M, Juang J, He L, Lin CT and Wu TC: CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination. Gene Ther 10: 1311-1320, 2003.
3. Cheng WF, Hung CF, Lee CN, Su YN, Chang MC, He L, Wu TC, Chen CA and Hsieh CY: Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways. Eur J Immunol 34: 1892-1900, 2004.
4. Algarra I, García-Lora A, Cabrera T, Ruiz-Cabello F and Garrido F: The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 53: 904-910, 2004.
5. Bubeník J, Mikysková R, Vonka V, Mendoza L, Símová J, Smahel M and Indrová M: Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16. Vaccine 21: 891-896, 2003.
6. Bubeník J: MHC class I down-regulation: tumour escape from immune surveillance? Int J Oncol 25: 487-491, 2004.
7. Bubeník J: Genetically modified cellular vaccines for therapy of human papilloma virus type 16 (HPV 16)-associated tumours. Curr Cancer Drug Targets 3: 180-186, 2008.
8. Koopman LA, Corver WE, van der Slik AR, Giphart MJ and Fleuren GJ: Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 191: 961-976, 2000.
9. Mocikat R, Braumüller H, Gumy A, Egeter O, Ziegler H, Reusch U, Bubeck A, Louis J, Mailhammer R, Riethmüller G, Koszinowski U and Röcken M: Natural killer cells activated by MHC class I (low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 19: 561-569, 2003.
10. Martini M, Testi MG, Pasetto M, Picchio MC, Innamorati G, Mazzocco M, Ugel S, Cingarlini S, Bronte V, Zanovello P, Krampera M, Mosna F, Cestari T, Riviera AP, Brutti N, Barbieri O, Matera L, Tridente G, Colombatti M and Sartoris S: IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine 28: 3548-3557, 2010.
11. Berg RE and Forman J: The role of CD8 T cells in innate immunity and in antigennon-specific protection. Curr Opin Immunol 18: 338-343, 2006.
12. Gerloni M and Zanetti M: CD4 T cells in tumor immunity. Springer Semin Immunopathol 1: 37-48, 2005.
13. Wendel M, Galani IE, Suri-Payer E and Cerwenka A: Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res 68: 8437-8445, 2008.
14. Reinis M, Símová J, Indrová M, Bieblová J, Pribylová H, Moravcová S, Jandlová T and Bubeník J: Immunization with MHC class I-negative but not -positive HPV16-associated tumour cells inhibits growth of MHC class I-negative tumours. Int J Oncol 30: 1011-1017, 2007.
15. Reinis M, Stepánek I, Símová J, Bieblová J, Pribylová H, Indrová M and Bubeník J: Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines. Int J Oncol 36: 545-551, 2010.
16. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HJ, August JT, Pardoll DM and Wu TC: Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56: 21-26, 1996.
17. Smahel M, Síma P, Ludviková V, Marinov I, Pokorná D and Vonka V: Immunisation with modified HPV 16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. Vaccine 21: 1125-1136, 2003.
18. Smahel M, Sobotková E, Bubeník J, Símová J, Zák R, Ludviková V, Hájková R, Kovarík J, Jelínek F, Povysil C, Marinov J and Vonka V: Metastatic MHC class I-negative mouse cells derived by transformation with human papilloma virus type 16. Br J Cancer 84: 374-380, 2001.
19. Mikysková R, Bubeník J, Vonka V, Smahel M, Indrová M, Bieblová J, Símová J and Jandlová T: Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy. Int J Oncol 26: 521-527, 2005.
20. Koo GC, Dumont FJ, Tutt M, Hackett J Jr and Kumar V: The NK-1.1(-) mouse: a model to study differentiation of murine NK cells. J Immunol 137: 3742-3747, 1986.
21. Dialynas DP, Quan ZS, Wall KA, Pierres A, Quintans J, Loken MR Pierres M and Fitch FW: Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J Immunol 131: 2445-2451, 1983.
22. Sarmiento M, Glasebrook AL and Fitch FW: IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cellmediated cytolysis in the absence of complement. J Immunol 125: 2665-2672, 1980.
23. Bubeník J, Zeuthen J, Indrová M, Bubeníková D and Símová J: Kinetics and function of peritoneal exudate cells during local IL-2 gene therapy of cancer. Int J Oncol 4: 13-16, 1994.
24. Indrová M, Mikysková R, Jandlová T, Vonka V, Bubeník J and Bieblová J: Adjuvant cytokine treatment of minimal residual disease after surgical therapy in mice carrying HPV16-associated tumours: cytolytic activity of spleen cells from tumour regressors. Folia Biol (Praha) 49: 217-222, 2003.
25. Indrová M, Reinis M, Bubeník J, Jandlová T, Bieblová J, Vonka V and Velek J: Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects. Folia Biol (Praha) 50: 184-193, 2004.
26. Indrová M, Bieblová J, Bubeník J and Reinis M: IL-12 immunotherapy of minimal residual disease in murine models of HPV16-associated tumours: induction of immune responses, cytokine production and kinetics of immune cell subsets. Int J Oncol 32: 499-507, 2008.
27. Indrová M, Bieblová J, Rossowska J, Kuropka P, Pajtasz-Piasecka E, Bubeník J and Reinis M: HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative response of tumour infiltrating cells after chemotherapy. Int J Oncol 34: 173-179, 2009.
28. Símová J, Bubeník J, Bieblová J and Jandlová T: The role of NK1.1+ cells in the protection against MHC class I+ HPV 16-associated tumours. Folia Biol (Praha) 50: 200-202, 2004.
29. Li Z, Pradera F, Kammertoens T, Li B, Liu S and Qin Z: Crosstalk between T cells and innate immune cells is crucial for IFNgamma-dependent tumor rejection. J Immunol 179: 1568-1576, 2007.